P&R of ODs is a challenging process, as the limited knowledge and heterogeneity of the diseases make it difficult to demonstrate the added clinical benefit of an OD [1]. This problem, added to the fact that ODs often fail to meet accepted cost-effectiveness criteria [2,3], has led to a number of exceptions the way ODs are appraised and resulted in differences between countries regarding clinical requirements and evaluations [1,4] .The aim of this work is to identify if the official criteria of Spanish P&R process are related with P&R approval for ODs.
Official P&R criteria are not always used by national authorities to reimburse an OD, as only for ODs to have less direct or indirect clinical trial outcomes showed to negatively influence reimbursement and the inclusion of the OD's manufacturer in the SPP showed to positively influence reimbursement. Budget Impact would be an important variable for reimbursement, but could not be assessed as information about sales forecast isn't public and published prices don't match the real ODs price.
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CONCLUSIONS REFERENCES
Clinical variables
Institutional variables Economic variables * Germany was excluded from the results analysis as ODs in Germany are reimbursed as soon as they enter the German market.
• All statistical analyses were consistent with the results, showing that two variables have an impact on reimbursement. The variables that can affect reimbursement are:
✓ Clinical trial outcomes classification (p<0,077): a less direct or indirect outcome decreases the probability of reimbursement.
✓ Manufacturer included in the SPP (p<0,094): the MAH of an OD to be included in the PP increases the probability of reimbursement.
• A total of 40 ODs were identified that had been approved by the EC between 2012-2016 and with marketing authorisation in Spain.
• From the identified ODs, 17 (42.5%) were reimbursed, 16 (40%) were undergoing reimbursement decision and 7 (17.5%) had reimbursement rejected.
• Potential variables that could influence reimbursement were classified according to the system described by Zozaya et. al.
[7] based on criteria for reimbursing orphan medicinal products. Clasif: Therapeutic Area Classification; ipt: Therapeutic Positioning Report; outcomes: Clinical Outcomes Classification; profarm: Profarma Plan; Reim: Reimbursement.
• Statistical analyses: a Probit regression model [8] was used to predict the impact of the studied variables on reimbursement in Spain and results were checked with a second analysis, an algorithm called Random Forest [9] . 
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